🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,60 EUR

Máx. histórico

912,40

63 días

Caída desde máximo

-10,61%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,07%

Cierre anterior

815,00

Rango de hoy

812,40 – 835,80

Volumen hoy

109.168

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,82 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
998,93 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 17 horas
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
17/09/2015 9,79 9,85 9,60 9,61 +0,42% 2,55% 5.015
16/09/2015 9,58 9,58 9,57 9,57 +0,00% 0,10% 1.352
15/09/2015 9,68 9,77 9,55 9,57 -1,03% 2,27% 3.459
14/09/2015 9,86 9,86 9,67 9,67 -2,62% 1,93% 1.787
11/09/2015 9,87 9,93 9,77 9,93 -0,50% 1,62% 1.939
10/09/2015 9,93 9,98 9,88 9,98 +0,60% 1,01% 1.339
09/09/2015 9,99 10,05 9,92 9,92 -0,30% 1,30% 2.064
08/09/2015 9,99 9,99 9,95 9,95 -1,00% 0,40% 95
07/09/2015 10,00 10,05 9,88 10,05 +0,50% 1,70% 1.064
04/09/2015 10,33 10,33 10,00 10,00 -2,34% 3,19% 979
03/09/2015 10,52 10,52 10,01 10,24 -0,58% 4,85% 2.630
02/09/2015 10,14 10,30 10,13 10,30 +1,58% 1,68% 5.906
01/09/2015 10,53 10,72 10,13 10,14 -1,65% 5,60% 3.281
31/08/2015 10,30 10,51 10,27 10,31 +1,78% 2,33% 1.577
28/08/2015 10,13 10,30 10,13 10,13 +0,00% 1,68% 77.001
27/08/2015 10,25 10,42 10,02 10,13 +1,20% 3,90% 7.023
26/08/2015 11,00 11,00 9,78 10,01 -2,91% 11,09% 10.662
25/08/2015 9,65 10,31 9,65 10,31 +7,17% 6,84% 3.207
24/08/2015 9,95 9,95 9,61 9,62 -3,51% 3,42% 6.187
21/08/2015 10,00 10,48 9,97 9,97 -0,70% 5,10% 5.450
20/08/2015 10,01 10,04 10,01 10,04 -1,28% 0,30% 1.265
19/08/2015 10,26 10,28 10,15 10,17 -0,88% 1,27% 1.437
18/08/2015 10,14 10,40 10,14 10,26 -0,97% 2,56% 2.174
17/08/2015 10,11 10,36 10,11 10,36 +1,17% 2,47% 1.340
14/08/2015 10,40 10,48 10,07 10,24 -1,54% 3,94% 1.667
13/08/2015 10,34 10,40 10,00 10,40 +4,00% 3,87% 3.418
12/08/2015 10,59 10,63 9,59 10,00 -7,83% 9,82% 26.633
11/08/2015 10,71 10,85 10,71 10,85 +1,31% 1,31% 505
10/08/2015 10,65 10,71 10,50 10,71 +0,09% 1,97% 2.148
07/08/2015 10,81 10,81 10,64 10,70 -0,09% 1,57% 1.266